Surzetoclax

DB21698InvestigationalSmall molecule

Surzetoclax is a small molecule drug. The usage of the INN stem '-toclax' in the name indicates that Surzetoclax is a B-cell lymphoma 2 (Bcl-2) inhibitor. Surzetoclax has a monoisotopic... Surzetoclax has a monoisotopic molecular weight of 1038.41 Da.

Mechanism: Pharmacologically active on Apoptosis regulator Bcl-2
Curator reviewed
Formula / weight: C₅₃H₆₃ClN₈O₁₀S · 1039.64 g/mol (avg)
Code names: ABBV-453

Resolves to

Compound

UNIIC3TU3CHH6LCAS2858632-01-4ChEMBLCHEMBL6068032ChEBI759950PubChem169450714

Structure

InChIKeyAWGQQZVAXXLVMT-ORYVFAGJSA-NSMILES

CO[C@@H]1CC[C@@H](CNC2=C(C=C(C=C2)S(=O)(=O)NC(=O)C2=C(C=C(C=C2)N2CCN3CC4=C(CC(C)(C)C[C@H]4OCCCOC[C@@H]3C2)C2=CC=C(Cl)C=C2)N2CCCOC3=C2C=C2C=CNC2=N3)[N+]([O-])=O)OC1

Targets

P10415BCL2

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Surzetoclax, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account